Navigation Links
Replidyne Pipeline Featured at 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
Date:9/17/2007

ed on its in-house discovery research.

Safe Harbor

This press release contains plans, intentions, objectives, estimates and expectations that constitute forward-looking statements about Replidyne, Inc. that involve significant risks and uncertainties. Actual results could differ materially from those discussed due to a number of factors including, the success and timing of pre-clinical studies and clinical trials; the Company's ability to obtain a new partner for faropenem on acceptable terms; the Company's ability to obtain and maintain regulatory approval of product candidates and the labeling under any approval that may be obtained; plans to develop and commercialize product candidates; the loss of key scientific or management personnel; the size and growth of the potential markets for the Company's product candidates and the Company's ability to serve those markets; regulatory developments in the U.S. and foreign countries; the rate and degree of market acceptance of any future products; the accuracy of Company estimates regarding expenses, future revenues and capital requirements; the Company's ability to obtain and maintain intellectual property protection for our product candidates; the successful development of the Company's sales and marketing capabilities; the success of competing drugs that are or become available; and the performance of third party manufacturers. These and additional risks and uncertainties are described more fully in the Company's most recent Form 10-Q filed with the SEC under the Securities Exchange Act of 1934. Copies of filings made with the SEC are available through the SEC's electronic data gather analysis and retrieval system (EDGAR) at http://www.sec.gov. All forward-looking statements made in the press release are made as of the date hereof and the Company assumes no obligation to update the forward-looking statements in the document.


'/>"/>
SOURCE Replidyne, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Replidyne Announces Positive Phase I Results for Topical Antibiotic REP8839
2. $30 M Aid in the pipeline by WB for bird flu in Turkey
3. AEternas acquisition of Zentaris being followed up with its new product pipeline and clinical development strategy
4. Battery power from viruses in the pipeline
5. Effective Vaccine for Leishmaniasis in the Pipeline
6. Home Test Kit for AIDS in the Pipeline
7. Sensing Devices to Measure Sleep In the Pipeline
8. Blood Fluke Vaccine in the Pipeline
9. Chlamydial Vaccine for Humans in the Pipeline
10. New Treatment Option in the Pipeline for Those Suffering From Lung Cancers
11. Treatment of Endometriosis in the Pipeline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... The Fresh Diet, America’s premier gourmet meal delivery ... meal plan. Originating from The Fresh Diet’s commitment to ... designed to satisfy customers seeking a convenient, worry-free option ... to the growing demand by customers for non-meat menu ... with 14% of Americans identifying vegetarian meals as ‘more ...
(Date:8/29/2014)... PA (PRWEB) August 29, 2014 As ... Cooper City, Fla., understands that there’s a direct connection ... the knees, hips and back. "Since conventional shoe inserts ... design a solution of my own," he said. , ... Orthotic provides better support for the foot in order ...
(Date:8/29/2014)... 29, 2014 Williams Rejuva Center is ... their Latham aesthetic office. Dr. Edwin Williams, known ... the first surgeons in the area to employ the ... technique is faster and safer than similar products available ... a noninvasive procedure , designed to dramatically improve ...
(Date:8/29/2014)... Glendale Botox experts at Glenoaks Laser Center are ... of September. This special offer features 10 free units of ... can take advantage of this special offer to completely transform ... work with patients to determine if Botox or Juvederm is ... , Botox is a treatment made from the botulinum toxin. ...
(Date:8/29/2014)... Dennis Thompson HealthDay Reporter ... research performed during the early days of the Ebola outbreak ... the virus mutates and spreads. Researchers report in the ... have now determined the following: The Ebola strains ... dating back to the very first recorded outbreak of Ebola ...
Breaking Medicine News(10 mins):Health News:The Fresh Diet America's #1 At-Home Meal Delivery Company, Debuts Fresh Vegetarian Meal Plan Offering All-Natural Ingredients 2Health News:The Fresh Diet America's #1 At-Home Meal Delivery Company, Debuts Fresh Vegetarian Meal Plan Offering All-Natural Ingredients 3Health News:Williams Revjuva Center Brings Micro-Needling to Latham 2Health News:Glenoaks Laser Center is Now Offering a Special Promotion on Botox for the Month of September 2Health News:Gene Research Yields Insights Into Ebola Virus 2Health News:Gene Research Yields Insights Into Ebola Virus 3
... Ky., Dec. 23 A group representing some of the ... drop language that would require vending companies to disclose the ... the point of sale, Vend Marketing Institute (VMI) Executive Director ... both the House and Senate versions of the healthcare reform ...
... for King Herod Himself , WASHINGTON, Dec. 23 As ... Reid,s health care bill, Family Research Council Action (FRC Action) ... call campaign in six states -- Nebraska, Arkansas, Louisiana, South ... to contact their Senators and tell them "don,t trade the ...
... Female janitors, scientists among those at highest risk, study ... working women in the United States, teachers seem to ... defects, while those who work as janitors, scientists and ... The study looked at nearly 9,000 babies born with ...
... ... conference provides First Responders with professional education and networking opportunity. , ... (PRWEB) December 23, ... Responders with professional education and networking opportunity., , ,Against a background of threats ...
... ... provider, today announced the appointment of a new leader who will help expand its ... ... debate rages on all sides of healthcare reform, one fact remains: the heavy lifting ...
... A McMaster University researcher has found the first evidence ... in car exhaust fumes and industrial air pollution can lead ... Infectious disease specialist Mark Loeb led a research team ... and sulfur dioxide, both found in motor vehicle emissions, and ...
Cached Medicine News:Health News:Vend Marketing Institute Calls on Congress to Modify Calorie Disclosure Requirement: Supports Existing Disclosure Which Is More Complete and Effective 2Health News:Vend Marketing Institute Calls on Congress to Modify Calorie Disclosure Requirement: Supports Existing Disclosure Which Is More Complete and Effective 3Health News:FRC Action Launches Last Minute Phone Call Campaign in Six States 2Health News:Mom's Job Could Boost Baby's Odds for Birth Defect 2Health News:5th Annual Homeland Security Professionals Conference and Exposition in Vegas on October 25-29 2010 2Health News:5th Annual Homeland Security Professionals Conference and Exposition in Vegas on October 25-29 2010 3Health News:New Executive Director to Lead Medical Education to Greater Relevance 2Health News:Air pollution linked to hospitalizations for pneumonia in seniors 2
(Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire-iReach/ -- ChemImage will present ... Australian and New Zealand Forensic Science Society,s 22 ... in Adelaide, Australia .  Forensic ... the advancements that hyperspectral imaging can bring to ... Beckstead , Director of Product Development at ChemImage, ...
(Date:8/29/2014)... 29, 2014 Research and Markets ... Sclerosis Drugs Market 2014-2018" report to their offering. ... medical condition that results in demyelination, axonal transection, and ... abnormal response by the immune system, which targets neurons ... potentially debilitating disease in which the damage of the ...
(Date:8/29/2014)...  In part four of a blog ... as a strategic asset, Mary Baxter, MBA, RPh ... Health,s Innovation Delivery Solutions business, discusses how expanding patient ... and patients. "Every hospital pharmacist knows that ... job in a value-based healthcare world," Baxter says. "For ...
Breaking Medicine Technology:ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 2Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 3Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 4
... NxStage Medical, Inc. (Nasdaq: NXTM ) a leading manufacturer of innovative dialysis products, today announced that it has secured a two-year $15 million revolving line of credit ... ... ... ...
... 11 Watson Pharmaceuticals, Inc. (NYSE: ... Administration (FDA) approval of TRELSTAR® 22.5 mg (triptorelin pamoate ... a proven, simple and effective palliative treatment of advanced ... mg is the first and only six-month intramuscular (IM) ...
Cached Medicine Technology:NxStage(R) Secures $15 Million Revolving Line of Credit 2NxStage(R) Secures $15 Million Revolving Line of Credit 3NxStage(R) Secures $15 Million Revolving Line of Credit 4FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 2FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 3FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 4FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 5FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 6FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 7FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 8
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: